10x Genomics is a biotechnology company offering a range of products including software and hardware all aimed at better understanding biological systems.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
01/07/2019 | Series D-1 | $35MM | $xx.xx | $1.34B | Fidelity, Meritech Capital, Wells Fargo | |
Price per Share
$xx.xx
Shares Outstanding
2,749,411
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fidelity, Meritech Capital, Wells Fargo
|
||||||
04/26/2018 | Series D | $50MM | $xx.xx | $1.31B | Fidelity International, Meritech Capital Partners, Paladin Capital Group, Phoenix International Investments, Softbank Capital, Wells Fargo | |
Price per Share
$xx.xx
Shares Outstanding
5,224,660
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fidelity International, Meritech Capital Partners, Paladin Capital Group, Phoenix International Investments, Softbank Capital, Wells Fargo
|
||||||
03/17/2016 | Series C | $55MM | $xx.xx | $400.05MM | Fidelity Management & Research Company, Foresite Capital Management, Js Capital Management, Paladin Capital Group, Softbank Capital, Venrock | |
Price per Share
$xx.xx
Shares Outstanding
12,281,720
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fidelity Management & Research Company, Foresite Capital Management, Js Capital Management, Paladin Capital Group, Softbank Capital, Venrock
|
||||||
01/12/2015 | Series B | $55.5MM | $xx.xx | $222MM | Foresite Capital Management, Morgan Stanley Alternative Investment Partners, Paladin Capital Group, Venrock, Vital Venture Capital | |
Price per Share
$xx.xx
Shares Outstanding
16,972,477
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital Management, Morgan Stanley Alternative Investment Partners, Paladin Capital Group, Venrock, Vital Venture Capital
|
||||||
10/30/2013 | Series A-2 | $22.4MM | $xx.xx | $56.05MM | Foresite Capital Management, Paladin Capital Group | |
Price per Share
$xx.xx
Shares Outstanding
20,486,543
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Foresite Capital Management, Paladin Capital Group
|
||||||
10/17/2012 | Series A-1 | $4.69MM | $xx.xx | $2.78MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
5,523,394
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|